Regulus Therapeutics Inc (NASDAQ:RGLS) traded at $7.84 at close of the session on Tuesday, May 13 and made a downward move of -0.38% on its previous day’s price.
Regulus Therapeutics Inc has a market cap of $542.79 million and is expected to release its quarterly earnings report in June.
On the other hand, looking at the outlook for the RGLS stock, short term indicators assign the stock an average of 100% Buy, while medium term indicators assign it an average of 100% Buy.
Based on estimates by 1 analysts, where scores have ranged from 1.00 for a strong buy to 5.00 for a strong sell, 0 have rated the Regulus Therapeutics Inc (RGLS) stock as a Hold, while 1 rate it as a Buy. 0 analyst(s) rate it as overweight while 0 of them rated it as underweight, whereas 0 suggest the stock as a Sell. The stock has an overall rating of Buy and investors could take advantage and scoop up stock of the company.
Looking further, we note the current price level is 50.93% off its SMA20 and 161.94% from its 50-day simple moving average. The RSI (14) is pointing at 91.56 while the volatility over the past week is 0.88% and jumps to 7.16% over the past one month. The beta value is 0.37, while the average true range (ATR) is currently pointing at 0.35. The average price target for the stock over the next 12 months is $7, with the estimates having a low of $7 and a high of $7. These price ends are 10.71% and 10.71% off the current price level respectively, although investors could be excited at the prospect of a 10.71% if the RGLS share price touches on the median price of $7.
